Clinical trials: Tauopathies
Alzheimer's Disease
Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
This study evaluated the safety and efficacy of 10 cm^2 rivastigmine patch in patients with Alzheimer Disease (MMSE 10-26). The primary objective was the percentage of patients who stayed on the target size of 10 cm^2 for at…
- Trial name
- ADEPT (NCT00561392)
- Testing
- Rivastigmine 5 and 10 cm^2 patch
- Where
- Germany
- Volunteers
- 208 people
- Sponsor
- Novartis
Alzheimer's Disease
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment of patients with Alzheimer's disease.
- Trial name
- NCT00814801
- Testing
- Galantamine 16 mg/day, Galantamine 24 mg/day
- Where
- Japan
- Volunteers
- 580 people
- Sponsor
- Janssen Pharmaceutical K.K.
Mild Cognitive Impairment
Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease
This is a proof of concept study to determine if changes in brain amyloid levels are evident three months after infusion of 0.4 g/kg of IVIG every 14 days x 5 infusions.
- Trial name
- NCT03319810
- Testing
- Octagam 10%
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sutter Health
Alzheimer's Disease
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test…
- Trial name
- NCT01561430
- Testing
- LY2886721
- Where
- 34 sites in United States, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)
This study is a Phase 2, randomized, placebo-controlled, dose-ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety…
- Trial name
- NCT02615002
- Testing
- Piromelatine
- Where
- 56 sites in United States
- Volunteers
- 371 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Alzheimer's Disease
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
The purpose of this study is to determine whether this drug can help symptoms of aggression and agitation in participants with Alzheimer's disease.
- Trial name
- NCT00843518
- Testing
- LY451395
- Where
- 17 sites in United States
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Dementia, Alzheimer's Disease
Indiana University Dementia Screening Trial
The purpose of the study is to conduct a randomized clinical trial assessing the harms and benefits of screening for dementia, compared to no screening for dementia, among 4,000 older adults, cared for in typical, primary care…
- Conditions
- Dementia, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- IU-CHOICE (NCT01699503)
- Testing
- Collaborative Dementia Care Program
- Where
- 3 sites in United States
- Volunteers
- 4,005 people
- Sponsor
- Indiana University
Alzheimer's Disease
A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects
This study will test if two flortaucipir PET scans up to 4 weeks apart in healthy volunteers, MCI and AD subjects provide the same results.
- Trial name
- NCT01992380
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease, Depression
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
This study will test the use of venlafaxine to treat the depression in Alzheimer's Disease. Venlafaxine works by increasing natural substances in the brain (serotonin and norepinephrine) that help maintain mental balance.
- Trial name
- DIADs-3 (NCT01609348)
- Testing
- Venlafaxine
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Dementia, Alzheimer Disease
Play Intervention for Dementia for Promoting Cognitive Function: A Feasibility Study
This study intends to use Play Intervention for Dementia (PID) to promote cognitive functions of people with early to moderate dementia.
- Trial name
- NCT02846415
- Testing
- Play Intervention for Dementia
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The Hong Kong Polytechnic University
Alzheimer's Disease
Riluzole in Mild Alzheimer's Disease
Cognitive aging is a major source of disability in an increasingly aging population. The paucity of effective treatments for cognitive aging disorders, and most importantly in Alzheimer's disease instigates a need for further…
- Trial name
- NCT01703117
- Testing
- Riluzole
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer Disease, Mild Cognitive Impairment
Noninvasive Brain Stimulation in Mild Cognitive Impairment and Dementia
The research objective of this study is to examine the efficacy of HD-tDCS to the preSMA/DACC region and its influence on verbal episodic memory in patients with MCI or dementia after 10 sessions of HD-tDCS.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- NCT05270408
- Testing
- Active Transcranial direct current stimulation (STARStim 8)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
This trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
- Trial name
- ADVANCE-2 (NCT05557409)
- Testing
- AXS-05
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 408 people
- Sponsor
- Axsome Therapeutics, Inc.
Progressive Supranuclear Palsy
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
The study will be conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy, (PSP).
- Trial name
- NCT05819658
- Testing
- GV1001 0.56mg, GV1001 1.12mg
- Where
- 5 sites in South Korea
- Volunteers
- 78 people
- Sponsor
- GemVax & Kael
Dementia
Preparation for End-of-Life Decision Making in Mild Dementia
The proposed study will adapt and pilot test an efficacious advance care planning interventions, Sharing Patient's Illness Representations to Increase Trust (SPIRIT), with patients with mild dementia and their surrogates to…
- Trial name
- NCT03311711
- Testing
- SPIRIT-in person, SPIRIT-remote, Usual care
- Where
- 5 sites in United States
- Volunteers
- 242 people
- Sponsor
- Emory University
Alzheimer Disease
Montelukast Therapy on Alzheimer's Disease
This is a one-year, double-blind placebo-controlled randomized clinical trial that compares montelukast to placebo in individuals with mild cognitive impairment (MCI) and early Alzheimer's disease (AD) dementia.
- Trial name
- NCT03991988
- Testing
- Montelukast
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Dementia, Alzheimer Type
Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE)
The specific aims of this study are 1) to test the trial and intervention feasibility of Brain Care Notes (BCN) app, 2) To estimate the effect size of BCN on reducing informal caregiver burden at 6 months, and 3) To estimate the…
- Trial name
- I-CARE (NCT03119259)
- Testing
- ABC Clinical Program, BCN
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Indiana University
Dementia, Alzheimer Disease
The Brain Health Study: A Pragmatic, Patient-Centered Trial
The eRADAR Brain Health Study seeks to refine and test a novel, low-cost strategy for increasing dementia detection within primary care.
- Trial name
- NCT05356702
- Testing
- Brain Health Assessment
- Where
- 5 sites in United States
- Volunteers
- 3,417 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either…
- Trial name
- NCT04374253
- Testing
- Gantenerumab
- Where
- 268 sites in United States, Argentina and 27 more
- Volunteers
- 1,382 people
- Sponsor
- Hoffmann-La Roche